Annual report
4564.TEDINET S100TSS9
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥610m | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥867m | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥3.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.1bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥514m | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥354m | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥528m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥528m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥795m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥31m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥96m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.86 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.73 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4.04 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥16.96 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥25.81 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 54 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 60 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 67 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 66 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 62 | at 2020-03-31d | Cons. | Number of employees |
| Operating income | −¥889m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | −¥873m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥507m | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥949m | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥154m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥374m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥354m | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥575m | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥325m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥297m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-4.74 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.8 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.13 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.58 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥14.53 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥23.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 55.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 217,643,700 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 27 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 36 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 35 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 32 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥270,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥270,000 |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥211m |
| Cancer Precision Medical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥155m |
| Cancer Precision Medical Businessreportable segment | employees | at 2024-03-31 | 27 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥610m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥610m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2024-03-31 | ¥407m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥236m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 27 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥698,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥427,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥270,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2024-03-31 | ¥459m |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥675m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥155m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥610m |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥610m |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥270,000 |
| —segment total | segment assets | at 2024-03-31 | ¥866m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥910m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥19m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥238,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥238,000 |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥344m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥381m |
| Cancer Precision Medical Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2m |
| Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2023-03-31 | ¥714m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥34m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥490,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥238,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2023-03-31 | ¥1.1bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥691m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥2m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥238,000 |
| —segment total | segment assets | at 2023-03-31 | ¥1.9bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | −¥725m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 27 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,207
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYearDuration | 39672000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -20319000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -33354000 | JPY |
| Payments for long term accounts payable other fin cf | Prior1YearDuration | － | JPY |
| Payments for long term accounts payable other fin cf | CurrentYearDuration | -4642000 | JPY |
| Proceeds from deposits received fin cf | Prior1YearDuration | 95950000 | JPY |
| Proceeds from deposits received fin cf | CurrentYearDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YearDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYearDuration | 682552000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YearDuration | － | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYearDuration | -6540000 | JPY |
| Other net fin cf | Prior1YearDuration | － | JPY |
| Other net fin cf | CurrentYearDuration | -2000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | 95950000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 671365000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -719271000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -589978000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1836906000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1117635000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1117635000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 527656000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 1 | |
| Outsourcing expenses research and development expenses | Prior1YearDuration | 355011000 | JPY |
| Outsourcing expenses research and development expenses | CurrentYearDuration | 382980000 | JPY |
| Payrolls and allowances research and development expenses | Prior1YearDuration | 127555000 | JPY |
| Payrolls and allowances research and development expenses | CurrentYearDuration | 117776000 | JPY |
| Patent costs research and development expenses | Prior1YearDuration | 114528000 | JPY |
| Patent costs research and development expenses | CurrentYearDuration | 101814000 | JPY |
| Commission fee sga | Prior1YearDuration | 90373000 | JPY |
| Commission fee sga | CurrentYearDuration | 89634000 | JPY |
| Directors compensations sga | Prior1YearDuration | 52680000 | JPY |
| Directors compensations sga | CurrentYearDuration | 56500000 | JPY |
| Payroll and allowances sga | Prior1YearDuration | 52144000 | JPY |
| Payroll and allowances sga | CurrentYearDuration | 56361000 | JPY |
| Taxes and dues sga | Prior1YearDuration | 144125000 | JPY |
| Taxes and dues sga | CurrentYearDuration | 4350000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 9134000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 1125769000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 1134903000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 1134903000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 238000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 238000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -238000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 9372000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 1125769000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 1135142000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -238000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |